These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6517228)

  • 21. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 22. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 23. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 24. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

  • 25. [Beta-thalassemia major in children and adolescents in Denmark].
    Jung A; Main KM; Scheibel E; Peitersen B; Clausen N; Erichsen G; Schmiegelow K; Illum N
    Ugeskr Laeger; 2002 Dec; 164(49):5803-6. PubMed ID: 12523224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary approaches to treatment of beta-thalassemia intermedia.
    Taher AT; Musallam KM; Karimi M; Cappellini MD
    Blood Rev; 2012 Apr; 26 Suppl 1():S24-7. PubMed ID: 22631038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG; Dashkova NG
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract]   [Full Text] [Related]  

  • 29. Tissue iron deposition in untransfused beta-thalassemic mice.
    Garrick LM; Strano-Paul LA; Hoke JE; Kirdani-Ryan LA; Alberico RA; Everett MM; Bannerman RM; Garrick MD
    Exp Hematol; 1989 Jun; 17(5):423-8. PubMed ID: 2714422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron metabolism and iron chelation in sickle cell disease.
    Walter PB; Harmatz P; Vichinsky E
    Acta Haematol; 2009; 122(2-3):174-83. PubMed ID: 19907155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma chitotriosidase activity in patients with beta-thalassemia.
    Barone R; Di Gregorio F; Romeo MA; Schilirò G; Pavone L
    Blood Cells Mol Dis; 1999 Feb; 25(1):1-8. PubMed ID: 10349508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infections and Cooley disease.
    Schiliro G; Romeo MA; Di Gregorio F; Sciacca A; Musumeci S; Russo G
    Birth Defects Orig Artic Ser; 1987; 23(5A):487-93. PubMed ID: 3318951
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

  • 35. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ; Kartikasari AE; Georgiou NA
    Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
    Graziano JH; Piomelli S; Hilgartner M; Giardina P; Karpatkin M; Andrew M; LoIacono N; Seaman C
    J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
    Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
    Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of iron overload in Cooley's anemia.
    Cohen A; Mizanin J; Schwartz E
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract]   [Full Text] [Related]  

  • 39. [The endocrine complications in thalassemia major].
    Anastasi S; Caruso V; Magnano C; Leocata A
    Pediatr Med Chir; 1991; 13(1):63-5. PubMed ID: 2052458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A noninvasive method for the evaluation of tissue iron deposition in beta-thalassemia major.
    Zeimer R; Belkin M; Leitersdorff E; Rachmilewitz EA
    J Lab Clin Med; 1978 Jan; 91(1):24-31. PubMed ID: 618988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.